436 related articles for article (PubMed ID: 19344187)
41. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.
Mathew M; Verma RS
Cancer Sci; 2009 Aug; 100(8):1359-65. PubMed ID: 19459847
[TBL] [Abstract][Full Text] [Related]
42. Cytotoxicity of recombinant Fab and Fv immunotoxins on adult T-cell leukemia lymph node and blood cells in the presence of soluble interleukin-2 receptor.
Saito T; Kreitman RJ; Hanada S; Makino T; Utsunomiya A; Sumizawa T; Arima T; Chang CN; Hudson D; Pastan I
Cancer Res; 1994 Feb; 54(4):1059-64. PubMed ID: 8313362
[TBL] [Abstract][Full Text] [Related]
43. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.
Onda M; Nagata S; FitzGerald DJ; Beers R; Fisher RJ; Vincent JJ; Lee B; Nakamura M; Hwang J; Kreitman RJ; Hassan R; Pastan I
J Immunol; 2006 Dec; 177(12):8822-34. PubMed ID: 17142785
[TBL] [Abstract][Full Text] [Related]
44. Immunoconjugates in the management of hairy cell leukemia.
Kreitman RJ; Pastan I
Best Pract Res Clin Haematol; 2015 Dec; 28(4):236-45. PubMed ID: 26614902
[TBL] [Abstract][Full Text] [Related]
45. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.
Foss FM
Ann N Y Acad Sci; 2001 Sep; 941():166-76. PubMed ID: 11594570
[TBL] [Abstract][Full Text] [Related]
46. Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation.
Kuan CT; Pastan I
Proc Natl Acad Sci U S A; 1996 Feb; 93(3):974-8. PubMed ID: 8577771
[TBL] [Abstract][Full Text] [Related]
47. Recombinant toxins.
Kreitman RJ; Pastan I
Adv Pharmacol; 1994; 28():193-219. PubMed ID: 8080817
[No Abstract] [Full Text] [Related]
48. Technology evaluation: BL22, NCI.
Barth S
Curr Opin Mol Ther; 2002 Feb; 4(1):72-5. PubMed ID: 11883697
[TBL] [Abstract][Full Text] [Related]
49. Targeted anticancer immunotoxins and cytotoxic agents with direct killing moieties.
Kawakami K; Nakajima O; Morishita R; Nagai R
ScientificWorldJournal; 2006 Jul; 6():781-90. PubMed ID: 16830050
[TBL] [Abstract][Full Text] [Related]
50. Clinical trials of targeted toxins.
Frankel AE; Tagge EP; Willingham MC
Semin Cancer Biol; 1995 Oct; 6(5):307-17. PubMed ID: 8562908
[TBL] [Abstract][Full Text] [Related]
51. Targeted toxins in brain tumor therapy.
Li YM; Hall WA
Toxins (Basel); 2010 Nov; 2(11):2645-62. PubMed ID: 22069569
[TBL] [Abstract][Full Text] [Related]
52. CLL immunotoxins.
Frankel AE; Kreitman RJ
Leuk Res; 2005 Sep; 29(9):985-6. PubMed ID: 16038723
[TBL] [Abstract][Full Text] [Related]
53. Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia.
Kreitman RJ; Arons E; Stetler-Stevenson M; Fitzgerald DJ; Wilson WH; Pastan I
Leuk Lymphoma; 2011 Jun; 52 Suppl 2(Suppl 2):82-6. PubMed ID: 21599609
[TBL] [Abstract][Full Text] [Related]
54. Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin.
Sarnovsky R; Tendler T; Makowski M; Kiley M; Antignani A; Traini R; Zhang J; Hassan R; FitzGerald DJ
Cancer Immunol Immunother; 2010 May; 59(5):737-46. PubMed ID: 20091030
[TBL] [Abstract][Full Text] [Related]
55. Immunotoxins.
Kreitman RJ
Expert Opin Pharmacother; 2000 Sep; 1(6):1117-29. PubMed ID: 11249483
[TBL] [Abstract][Full Text] [Related]
56. Recombinant immunotoxins: new therapeutic agents for cancer treatment.
Pastan IH
Cancer Detect Prev; 1993; 17(2):289-93. PubMed ID: 8402714
[TBL] [Abstract][Full Text] [Related]
57. Immunotoxins and recombinant toxins in the treatment of solid carcinomas.
Theuer CP; Pastan I
Am J Surg; 1993 Sep; 166(3):284-8. PubMed ID: 8368439
[TBL] [Abstract][Full Text] [Related]
58. Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2).
Robbins DH; Margulies I; Stetler-Stevenson M; Kreitman RJ
Clin Cancer Res; 2000 Feb; 6(2):693-700. PubMed ID: 10690555
[TBL] [Abstract][Full Text] [Related]
59. In vivo studies with chimeric toxins. Interleukin-2 fusion toxins as immunosuppressive agents.
Shapiro ME; Kirkman RL; Kelley VR; Bacha P; Nichols JC; Strom TB
Targeted Diagn Ther; 1992; 7():383-93. PubMed ID: 1633300
[No Abstract] [Full Text] [Related]
60. Chimeric fusion proteins--Pseudomonas exotoxin-based.
Kreitman RJ
Curr Opin Investig Drugs; 2001 Sep; 2(9):1282-93. PubMed ID: 11717817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]